Pre-Conference Workshop

Tuesday, January 25

02:00 pm – 04:00 pm

Next-Generation Regulatory Genome Targets for Cardiac Fibrosis

Myocardial fibrosis is a remarkably dynamic process mediated by different molecular pathways that represent potential targets of novel therapeutic interventions. A variety of pre-clinical evidences suggest that new drugs and molecules are potentially useful to target cardiac fibrosis and improve left ventricular function, reduce infarct size and scars, delay incident heart failure and cardiac dysfunction in animal models. However, there are very few clinical trials investigating the effect of such drugs in this setting, as well as a lack of new engineered molecules for specific targets

This workshop will delve directly into targeting recent advances and novel therapeutic approaches to treat cardiac fibrosis in heart failure with preserved ejection fraction (HFpEF); and their underlying molecular mechanisms

Attend this expert-led session on molecular biology to:

  • Explore the pathophysiology and clinical implications of interstitial fibrosis in HFpEF
  • Gain an overview of trials targeting fibrosis in HFpEF to date and discuss the promise of potential new therapeutic approaches and targets in the context of underlying molecular mechanisms

Workshop Leader

Samir Ounzain

Samir Ounzain, Co-Founder, HAYA Therapeutics

Scientific Co-Founder and CEO of HAYA Therapeutics. HAYA Therapeutics is a precision therapeutics company that discovers and develops innovative tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging. The company’s discovery engine focuses on long non-coding RNAs (lncRNAs) within the “dark matter” of the human genome - key tissue and cell-specific drivers of fibrosis and other disease processes - to identify novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments.